Yahoo · Oct 26, 2026
Labcorp inks Millennium Health buyout to add drug testing services
The proposed acquisition of the specialty laboratory is the third Labcorp buyout announced in eight days.
MY
NASDAQ · MYGN
Myriad Genetics, Inc.
Healthcare · Medical - Diagnostics & Research
$5.85
Down-$0.50 (-7.87%)
Updated Nov 3, 2026, 5:21 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 680.86M
- P/E ratio
- -1.71
- Dividend yield
- 0.00%
- 52-week range
- $2.74 – $8.38
- Volume
- 1.35M
- Avg. volume
- 1.22M
Price performance · MYGN
MYGN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
MYGN closed at $5.85 after 21 trading sessions, up 27.73% for the selected period.
- Last close
- $5.85
- Period change
- +27.73%
- Period low
- $3.98
- Period high
- $6.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $6.36 | $6.4616 | $5.82 | $5.85 | 1.35M |
| Oct 30, 2026 | $6.51 | $6.66 | $6.28 | $6.35 | 1.5M |
| Oct 29, 2026 | $6.63 | $6.77 | $6.455 | $6.67 | 1.47M |
| Oct 28, 2026 | $6.24 | $6.65 | $6.19 | $6.63 | 2.5M |
| Oct 27, 2026 | $6.02 | $6.34 | $5.97 | $6.29 | 2.24M |
| Oct 26, 2026 | $5.82 | $6.07 | $5.7824 | $6.02 | 1.49M |
| Oct 23, 2026 | $5.72 | $5.855 | $5.60 | $5.82 | 2.1M |
| Oct 22, 2026 | $5.57 | $5.93 | $5.39 | $5.76 | 4.44M |
| Oct 21, 2026 | $5.60 | $5.7432 | $5.45 | $5.57 | 4.95M |
| Oct 20, 2026 | $5.34 | $5.95 | $5.25 | $5.54 | 24M |
| Oct 19, 2026 | $4.01 | $4.235 | $3.95 | $4.21 | 1.36M |
| Oct 16, 2026 | $4.345 | $4.345 | $3.97 | $3.98 | 1.43M |
| Oct 15, 2026 | $4.20 | $4.42 | $4.11 | $4.35 | 1.07M |
| Oct 14, 2026 | $4.08 | $4.285 | $4.04 | $4.15 | 1.86M |
| Oct 13, 2026 | $4.20 | $4.215 | $4.05 | $4.08 | 1.38M |
| Oct 12, 2026 | $4.30 | $4.32 | $4.19 | $4.20 | 1.38M |
| Oct 9, 2026 | $4.18 | $4.40 | $4.15 | $4.31 | 1.37M |
| Oct 8, 2026 | $4.24 | $4.255 | $4.05 | $4.20 | 2.26M |
| Oct 7, 2026 | $4.25 | $4.32 | $4.12 | $4.28 | 1.6M |
| Oct 6, 2026 | $4.62 | $4.826 | $4.22 | $4.28 | 1.8M |
| Oct 5, 2026 | $4.51 | $4.615 | $4.409 | $4.58 | 2.76M |
Latest MYGN news
The latest Smart Investors Daily articles mentioning MYGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MYGN research
Overview
Company profile and research snapshot.
Company profile
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Hold | — |
| Oct 2, 2026 | Craig-Hallum | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Sep 1, 2026 | Piper Sandler | Underweight | — |
| Aug 18, 2026 | Stephens & Co. | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and
Yahoo · Oct 22, 2026
Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions
For Myriad Genetics, recent analyst updates around fair value and price targets now cluster mostly in the US$4 to US$8 range, compared with a prior fair value estimate of US$3.91 that has been reset to US$4.49. These shifts link directly to mixed analyst reactions to the Prenatal Health divestiture, revised 2026 revenue guidance, and ongoing questions about growth visibility and profitability. As you read on, you will see how these moving price targets fit into the broader narrative and how...
Yahoo · Oct 22, 2026
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgerySALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to sup
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
